The industry’s focus is on living organisms. The highly regulated standards make it a distinct consideration for business executives. These attributes make the industry a natural source of innovations, which has led to major breakthroughs which have improved the quality of http://genotec-frankfurt.de/crispr-genome-editing agriculture, led to the creation of biofuels and helped to create life-saving pharmaceutical products.

Start-up biotech companies have many options when it comes down to revenue generation strategies, with the majority choosing either a technology partnering or an asset creation and out-licensing approach. Technology partnering can result in more revenue and lower risk to the financials, whereas asset creation and outlicensing strategies can yield higher returns. A growing number of biotechs at the research phase employ a hybrid approach that combines these two approaches.

If you choose to go with the approach of developing based on products will succeed commercially if they can get their pipeline up to the right stage and find a Pharma partner or an investor with deep pockets. This could be expensive however, and making sure that you balance opportunistic methods to leverage outside assets with the right scientific decision-making about projects that are homegrown is crucial.

Alternately, the “platform” model provides an alternative path to revenue. It is a less expensive alternative to the product-oriented approach but it comes with significant risk. In this model biotechs have the ability to develop their own platform technology before teaming with pharma giants to create a range of drug discovery projects aimed at specific diseases (i.e. disease x is a biological condition that causes). This is the model Advinus Therapeutics and a few others have taken.